- Flow Health Science presented at three separate ADA 2026 sessions — including a research poster, the Innovation Challenge, and the Innovation Theatre — while engaging with thousands of diabetes care professionals.
- The team held hundreds of conversations with clinicians and ADA leadership, reinforcing that hypoglycemia care deserves greater clinical focus and better tools.
- Klario® is now commercially available, with peer-reviewed evidence including a 27% reduction in recurrent hypoglycemia across more than 1,000 episodes.
London, UK – Flow Health Science, the London-based company behind Klario®, made its most significant appearance to date at the American Diabetes Association Scientific Sessions 2026, presenting across three platforms and engaging with the global diabetes care community on the urgent need to raise the standard of hypoglycemia management.
The Flow Health Science team presented a research poster showcasing the patient-reported outcomes from the Klario study, competed in the ADA Innovation Challenge, and took the stage at the ADA Innovation Theatre; three distinct opportunities to bring the evidence behind Klario to one of the world’s most influential audiences in diabetes medicine. The team also met with ADA leadership and Breakthrough T1D.
Beyond the formal sessions, the team engaged in hundreds of conversations with diabetes care professionals — clinicians, researchers, and specialists from across the globe — sharing insights on hypoglycemia recovery and the growing recognition that current approaches to hypoglycemia management leave meaningful gaps in patient outcomes.
ADA 2026 gave Flow Health Science the opportunity to bring its evidence base directly to global clinicians, researchers, and healthcare decision-makers. Findings from the 12-week randomised study, including a 27% reduction in recurrent hypoglycemia and significantly faster return to normal activities, underline the case for raising the standard of hypo care beyond glucose correction alone.
“The conversations we had at ADA only strengthened our belief that hypo care deserves greater focus, better tools, and a higher standard of care.” — Georgia Myers, CEO at Flow Health Science
The engagement at ADA 2026 forms part of a wider commitment by Flow Health Science to contribute to the scientific and clinical communities shaping the future of hypoglycemia management. The company will continue presenting its evidence base at international conferences and in peer-reviewed settings throughout 2026.
Klario® is available now at www.myklario.com.
About the Product
Klario®: A Novel Approach to Hypoglycaemia Management
Hypoglycemia represents a critical therapeutic challenge in diabetes management: people with T1D may experience 100–200 treatment-related episodes annually. Current recommended therapeutic interventions using glucose-only treatments frequently result in suboptimal outcomes, including rapid glucose fluctuations, persistent neuroglycopenic symptoms, and fear-driven non-adherence to medication. Klario, a novel multi-substrate energy formulation combining glucose with BHB, was designed to achieve more complete recovery from hypoglycemia. In line with medical guidelines, Klario delivers 15 grams of fast-acting carbs to raise blood glucose quickly, while also raising BHB levels acutely. This combination formula improves glycemic control in the immediate post-treatment period and provides rapid, sustained neuroglycopenic recovery. For more information about Klario, please visit myklario.com.
About Flow Health Science
Flow Health Science is dedicated to transforming health outcomes through trusted, clinically-proven functional foods. Grounded in advanced metabolic science, our research and pipeline targets diabetes management, fatigue, hormone imbalances, and broader metabolic dysfunction.
Media Contact: Tara Lumley, Chief Strategy & Business Officer — press@flowhealthscience.com
Source: Flow Health Science